A mosquito-borne viral infection causing high fever and severe muscle pain. The Dengvaxia controversy highlighted complex challenges in dengue vaccination.
Dengue is a mosquito-borne viral infection caused by four related dengue viruses (DEN-1, DEN-2, DEN-3, DEN-4). It is transmitted by Aedes aegypti and Aedes albopictus mosquitoes. The disease affects millions of people annually, primarily in tropical and subtropical regions (CDC, 2024).
According to WHO, dengue has become a major international public health concern. There are estimated 100-400 million infections annually in over 100 endemic countries. Severe dengue (dengue hemorrhagic fever) can be life-threatening without proper medical care.
Vaccination remains the most effective preventive strategy for dengue in eligible populations. The following describes established medical consensus for clinical management for those who contract infection.
No antiviral treatment exists for dengue. Management is supportive — strict isotonic fluid management with oral or intravenous rehydration is central to preventing dengue hemorrhagic fever. Critical warning: NSAIDs including aspirin and ibuprofen must be avoided due to hemorrhage risk. Paracetamol (Acetaminophen) is the only recommended antipyretic. Close monitoring of platelet counts and hematocrit is essential during the critical phase (days 3-7 of illness).
Disclaimer: This information is for educational purposes only. Treatment decisions must be made by a qualified healthcare provider.